when was semaglutide approved FDA Warns on Certain Forms of Compounded FDA-Approved Oral Semaglutide: The First

Always double-check your sequence before starting synthesis

Focus on next-generation products Novo is investing in next-generation GLP-1 therapies, including oral semaglutide formulations and combination drugs like CagriSema, which may offer enhanced efficacy compared to current products

What type of exercise is best on a GLP-1 medication

What the Science Actually Shows (And Doesn't Show) BPC-157: The Most-Hyped Peptide What we know from animal studies: Promotes blood vessel growth (angiogenesis) Reduces inflammation Speeds healing in tendons, ligaments, muscles, gut Protects organs from damage Published studies: 100+ papers The problem: All from ONE research group (Dr

Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment